Theravance Biopharma Inc Total Liabilities
Theravance Biopharma Inc total liabilities. Based on the latest financial reports, Theravance Biopharma Inc (0TB) has total liabilities worth €182.78 Million EUR (≈ $213.69 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Theravance Biopharma Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Theravance Biopharma Inc (2014–2024)
Total liabilities of Theravance Biopharma Inc from 2014 to 2024. This chart illustrates how Theravance Biopharma Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Theravance Biopharma Inc (0TB) long-term investment share to see how much of total assets are deployed in long-term investments.
Theravance Biopharma Inc Competitors by Total Liabilities
The table below lists competitors of Theravance Biopharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Xinjiang Baodi Mining Co. Ltd. A
SHG:601121
|
China | CN¥4.17 Billion |
|
CTT Correios de Portugal SA
LS:CTT
|
Portugal | €5.53 Billion |
|
Foschini Group Ltd
JSE:TFG
|
South Africa | ZAC35.30 Billion |
|
Hunan Changgao High Voltage Switchgear Group Co Ltd
SHE:002452
|
China | CN¥1.73 Billion |
|
Montnets Cloud Technology Group Co Ltd
SHE:002123
|
China | CN¥1.58 Billion |
|
Heritage Commerce Corp
NASDAQ:HTBK
|
USA | $5.06 Billion |
|
Abacus Global Management, Inc.
NYSE:ABX
|
USA | $428.05 Million |
|
Abacus Life Inc.
NASDAQ:ABL
|
USA | $479.34 Million |
Liability Composition Analysis (2014–2024)
This chart breaks down Theravance Biopharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Theravance Biopharma Inc total assets.
Liquidity & Leverage Metrics
Theravance Biopharma Inc Total Liabilities Ratios Explained
Theravance Biopharma Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.48 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.79 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.44 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Theravance Biopharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Theravance Biopharma Inc (2014–2024)
The table below shows the annual total liabilities of Theravance Biopharma Inc from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €178.62 Million ≈ $208.82 Million |
+5.69% |
| 2023-12-31 | €169.00 Million ≈ $197.58 Million |
+2.06% |
| 2022-12-31 | €165.60 Million ≈ $193.60 Million |
-76.79% |
| 2021-12-31 | €713.39 Million ≈ $834.03 Million |
-7.69% |
| 2020-12-31 | €772.81 Million ≈ $903.49 Million |
+22.15% |
| 2019-12-31 | €632.67 Million ≈ $739.65 Million |
+3.41% |
| 2018-12-31 | €611.82 Million ≈ $715.29 Million |
+87.55% |
| 2017-12-31 | €326.22 Million ≈ $381.39 Million |
+12.87% |
| 2016-12-31 | €289.02 Million ≈ $337.90 Million |
+406.60% |
| 2015-12-31 | €57.05 Million ≈ $66.70 Million |
+18.90% |
| 2014-12-31 | €47.98 Million ≈ $56.10 Million |
-- |
About Theravance Biopharma Inc
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). Its late-stage investigational once-daily norepinephrine reuptake inhibitor, Ampreloxetine is in the development for symptomatic neurogeni… Read more